Key facts
- Migrevention’s last known valuation is $3.9M (Oct 2021).
- It has raised $740K; the latest was Seed Round ($320K) in Dec 2025.
- Notable investors include European Commission, Ajujaht, Challenger Accelerator, Dag Nurm, Health Founders — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Migrevention
- ·The full record, as it builds
Funding rounds
No funding rounds for Migrevention are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Migrevention
Developer of digital clinical management software designed for primary headache care. The company's platform combines a clinically validated patient-facing medical technology with provider management tools, including digital headache diaries, symptom and trigger tracking, secure data sharing, and aggregated data capabilities, enabling patients to improve understanding, coordination, and efficiency of headache diagnosis, treatment, and disease management.
- Sector
- Healthcare
- HQ
- Tartu, Estonia
- Founded
- 2020
- Employees
- 8
- Website
- migrevention.com/
- Ownership
- Privately Held (backing)
Migrevention doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Migrevention shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Migrevention in its N-PORT filings yet. We sweep new filings monthly.